Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates
- Successful clinical efficacy demonstrated for LDX compound in treating dialysis-related symptoms
- Large market opportunity with dialysis treatment market projected to reach $198.2B by 2033
- Partnership with Athena GTX for advanced monitoring technology integration
- Expanding potential applications of LDX beyond initial PTSD/Suicidal Ideation focus
- Early stage of clinical studies with limited patient data
- FDA approval still pending for LDX compound
- Competitive market with established treatment options
Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease
JACKSON CENTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) in cooperation with Athena Telemedicine Partners, LLC, announces astounding clinical efficacy for our patent-pending LDX compound for dialysis-borne neuropathy and pruritis in yet another case report and issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease.
We previously found that our patent-pending LDX medication is an incredibly ubiquitous compound that has powerful applications in the management of addiction, chronic inflammatory disorders, neurological disorders, pain management and represents a multibillion-dollar market potential. We recognize that it is important to satisfy FDA indications and advance other unforeseen and profitable indications as we continue to expand the potential use of our proprietary LDX formulation. Following is our recent experimentation with LDX beyond our previous successful program on PTSD/Suicidal Ideation.
The Problem: As of recent estimates, approximately 850 million people worldwide suffer from some form of kidney disease, including chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage kidney failure. International Society of Nephrology
Chronic Kidney Disease (CKD): In 2021, there were approximately 673.7 million cases of CKD globally. CKD is characterized by abnormalities in kidney structure or function lasting for more than three months and is a leading cause of kidney failure. Frontiers.
End-Stage Kidney Failure: Over 2 million people currently receive treatment for kidney failure through dialysis or kidney transplantation. However, this number may represent only about
Acute Kidney Injury (AKI): Each year, 13.3 million people experience AKI, which can lead to CKD or kidney failure if not properly managed. International Society of Nephrology
As of 2023, approximately 4.2 million people worldwide are undergoing dialysis treatments for end-stage kidney failure, according to Fresenius Medical Care. This figure includes both hemodialysis and peritoneal dialysis patients. Notably, about
Case Report: LD is a 63 y/o female with Stage 4 chronic renal failure on home peritoneal dialysis with severe symptoms of pruritis and neuropathy. Unresponsive to large doses of multiple medications, including Gabapentin, she was placed on LDX and a custom CBD nutraceutical. For the first time in five years, she became almost immediately symptom free.
However, LD stopped the LDX based on physician input, and had a recurrence of her symptoms. She was hospitalized for hypertension and stabilized, a significant reduction in medications prescribed ensued, including Gabapentin, and as a result her neuropathy and pruritic symptoms reappeared. She was started on LDX again, but under a titrated dose response protocol that is patent pending, and immediately found relief of both the pain and itching.
We will be offering a 90-day trial for clinicians dealing with dialysis patients on a safety and proof of efficacy FDA study for LDX. Our platform involves a very low dose initiation and progressive introduction of LDN and methocarbamol with natural cinnamon as a filler to a traditional therapeutic dose.
Athena GTX will be supplying wearable WatchDawg™ monitoring and cloud-based acquisition of data through our partners at Verizon, to supply objective data on the relief of symptoms to both the participants and physicians/care teams. We expect a full data presentation for a large and heretofore patient problem that was very difficult to manage.
This will be one of two studies with which we are engaged, with a subsequent well-funded study on PTSD, alcohol use disorder, and suicidal ideation, with an end goal to reduce suicide to be announced shortly.
To get the latest on the exciting developments by the Halberd/Athena teams, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/).
For more information, please contact:
| William A. Hartman | Mark Darrah, PhD |
| Chairman, CEO, President, Halberd Corp. | CEO Athena GTX |
| w.hartman@halberdcorporation.com | GM Athena Telemed. Partners (LLC) |
| support@halberdcorporation.com | mdarrah@athenagtx.com |
| www.halberdcorporation.com | www.athenagtx.com |
| Twitter:@HalberdC | |
About Athena Telemedicine Partners, LLC
Athena Telemedicine Partnership, LLC (ATP) is a partnership between Athena GTX, Inc. and three other partners and a group of private investors. The partnership involves the use of pharmaceuticals, nutraceuticals, yoga/meditation, unique, wearable monitoring, and psychological therapists combining to service veteran mental health issues and suicidal ideation.
About Athena GTX, Inc.
Athena GTX is a certified DoD small business with Corporate Headquarters in Johnston, Iowa. Athena focuses development on wearables and highly mobile, wirelessly connected monitoring technologies, and transitioning those to key markets to meet unmet needs of first responders worldwide. Wireless Patient Monitoring – Athena GTX connects patient and provider About - Athena GTX® Inc.
About Halberd Corporation.
Halberd Corporation (OTC: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners. Halberd’s policy for responding to individual shareholder questions is to be responsive, while refraining from providing information which relates to or could compromise any information pertaining to trade secrets or that may otherwise compromise our competitive advantages. Simultaneously with such disclosure or potential disclosure, Halberd will make the responsive information public through a tweet, press release or some other form of social media/mass media communication.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company’ cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2025, Halberd Corporation
FAQ
What is Halberd's (HALB) LDX compound being tested for in the new clinical study?
How large is the market opportunity for Halberd's (HALB) kidney disease treatment?
What technology will be used in Halberd's (HALB) kidney disease clinical trial?
What were the results of the case study for Halberd's (HALB) LDX compound?
How will Halberd (HALB) conduct the 90-day clinical trial for kidney disease patients?
